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Abstract
Rift Valley fever (RVF), a re-emerging mosquito-borne disease of ruminants and man, was endemic in Africa but spread to
Saudi Arabia and Yemen, meaning it could spread even further. Little is known about innate and cell-mediated immunity to
RVF virus (RVFV) in ruminants, which is knowledge required for adequate vaccine trials. We therefore studied these aspects
in experimentally infected goats. We also compared RVFV grown in an insect cell-line and that grown in a mammalian cell-
line for differences in the course of infection. Goats developed viremia one day post infection (DPI), which lasted three to
four days and some goats had transient fever coinciding with peak viremia. Up to 4% of peripheral blood mononuclear cells
(PBMCs) were positive for RVFV. Monocytes and dendritic cells in PBMCs declined possibly from being directly infected with
virus as suggested by in vitro exposure. Infected goats produced serum IFN-c, IL-12 and other proinflammatory cytokines
but not IFN-a. Despite the lack of IFN-a, innate immunity via the IL-12 to IFN-c circuit possibly contributed to early
protection against RVFV since neutralising antibodies were detected after viremia had cleared. The course of infection with
insect cell-derived RVFV (IN-RVFV) appeared to be different from mammalian cell-derived RVFV (MAM-RVFV), with the
former attaining peak viremia faster, inducing fever and profoundly affecting specific immune cell subpopulations. This
indicated possible differences in infections of ruminants acquired from mosquito bites relative to those due to contact with
infectious material from other animals. These differences need to be considered when testing RVF vaccines in laboratory
settings.
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Introduction
Rift Valley fever (RVF) is a disease of ruminants and man
caused by the mosquito transmitted Rift Valley fever virus
(RVFV), genus Phlebovirus, family Bunyaviridae [1]. This spherical
shaped, enveloped virus has a negative-sense single-stranded RNA
genome made up of 3 segments. The large (L) segment encodes for
the viral RNA-dependent RNA polymerase while the medium (M)
segment encodes the external glycoproteins (Gn and Gc) and the
non-structural protein (NSm). The small (S) segment is ambisense,
coding for the nucleoprotein (N) in the antigenomic sense and the
non-structural protein (NSs) in the genomic direction [2].
RVF outbreaks are frequently reported in Sub-Saharan
African countries where the disease is endemic. These include
Kenya, Tanzania, Somalia, South Africa, Sudan, Uganda,
Madagascar and Senegal. However, outbreaks were also reported
in Egypt, Yemen and Saudi Arabia indicating an expanding
range for this disease [3]. RVFV is transmitted primarily by Aedes
and Culex mosquitoes, with the latter serving as a magnifying host
during outbreaks [2] . In addition to infectious mosquito bites,
humans can also acquire RVF through contact with blood of
diseased animals [4,5]. Outbreaks of RVF in endemic countries
usually coincide with conditions such as periods of heavy rainfall
and flooding, which favour heavy breeding of mosquito vectors
[6,7].
RVF is characterized by large abortion storms and close to
100% mortality in newborn sheep, goats and cattle resulting in
severe adverse socio-economic effects [8]. These animals carry
high titres of virus (6 log10 to 8 log10 PFU/mL) in their blood
resulting in fever, inappetence, nasal discharges and diarrhoea [3].
However, adult sheep, goats and cattle are more resistant to
RVFV and experience lower mortality rates between 10–30% [3].
Human RVF usually manifests as a mild and self-limiting fever,
but in some patients may progress to a haemorrhagic fever,
neurological disorder or blindness [2,3].
Innate and adaptive immune responses contribute to the
clearance of RVFV in infected animals [3,9]. Evidence for the
role of innate immunity is mostly based on results from
experimental models [9–12]. Interferon alpha (IFN-a) is believed
to protect against RVFV because monkeys that secreted this
cytokine within 12 h of being challenged with RVFV did not
develop disease [11]. However, RVFV NSs protein inhibits IFN-
a and IFN-b production/induction, thereby enabling early
replication and viremia [12–14]. Anti-RVFV antibodies are
detectable 4 to 8 days following infection [15–17]. Neutralising
antibodies are believed to be crucial for the protection of infected
animals [2,11].
Although ruminants have since been recognized as the primary
animal hosts, there is little knowledge of the pathogenesis of
RVFV in goats. In 2–3 months old goats experimentally infected
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inoculation and lasted for 3 days [18]. These goats also had a
mild transient increase in rectal temperature. Mild fever was
equally observed in goats inoculated by inhalation and virus
could be recovered from throat washes 2 days after inoculation
[18]. In addition, virus was apparently transmitted to contact
goats. Clinical signs varied in severity depending on the route of
inoculation and included lethargy, diarrhoea and occlusion of the
eyes. All the goats died between days 9 and 70 post inoculation
possibly due to RVF but secondary infections could have also
contributed to these deaths. Gross and histopathology lesions
were observed in the liver, lungs, kidneys, spleen and brain of
infected goats [18]. An attenuated live RVFV vaccine (Smithburn
strain) has also been shown to cause abortion in vaccinated
pregnant goats and pathology in the liver, kidney and other
organs of vaccinated kids [19].
There is still a remarkable paucity of data on RVFV innate and
cell mediated immune responses in sheep, goats and cattle.
Knowledge of the pathogenesis and immune response to RVFV in
these domestic ruminants is crucial for rational design of new
vaccines and/or evaluation of existing vaccines for veterinary and
human use. Therefore, to better understand RVF in small
ruminants, we performed experimental infection of goats with
RVFV.
The C-type lectins, DC-SIGN and L-SIGN have been
identified as probably receptors for arthropod borne viruses
(arboviruses) [20]. Similarly, DC-SIGN has recently been
identified as a receptor for Phleboviruses including RVFV [21].
Furthermore, insect cell-derived arboviruses belonging to the
Alphavirus genus were more infectious to monocyte-derived
dendritic cells (MoDCs) compared to mammalian cell-derived
virus [20,22] possibly due to their stronger recognition and
binding to the C-type lectin receptors. In addition, insect cell-
derived Alphavirus was poor at inducing type 1 interferon responses
in MoDCs, further enhancing its ability to replicate in these cells
[22]. These data collectively suggest that there might be
differences between insect cell-derived and mammalian cell-
derived arbovirus in in vivo infectivity and disease pathogenesis in
susceptible animals. To investigate this, we inoculated goats with
insect cell-derived and mammalian cell-derived RVFV and
monitored in vivo differences in the course of infection. In addition,
we evaluated RVFV from these 2 sources for differences in in vitro
infectivity of MoDCs.
Materials and Methods
Ethics statement
All animal experiments were carried out in enhanced biosafety
level 3 (BSL3+) at the National Centre for Foreign Animal Disease
(NCFAD) Winnipeg, Manitoba. All protocols for animal use,
under animal use document (AUD) number C-09-004, were
approved by the Canadian Science Center for Human and
Animal Health, Winnipeg, Manitoba, Canada Animal Care
Committee. Only the NCFAD veterinarian and trained animal
care personnel were allowed access to the animals. Care was taken
to minimise animal suffering, respecting the Canadian Council on
Animal Care guidelines for animal manipulations.
Virus production and titration
RVFV strain ZH501 [23] was kindly provided by Dr Heinz
Feldmann, National Microbiology Laboratory, Winnipeg,
Canada.
The mammalian cell-derived RVF virus (MAM-RVFV) was
propagated on Vero E6 cells (American Tissue Culture Collection,
ATCC, Manassas, VA, USA). Infection of Vero E6 cells with
RVFV was done in dulbecco’s modification eagle’s medium
(DMEM) supplemented with 0.3% bovine serum albumin (BSA,
Wisent, QC, Canada) at an MOI of 0.1 and the cultures
maintained in DMEM with 0.3% BSA at 37uC, 5% CO2 and 95%
relative humidity. The virus eventually used as inoculum for goats
was from the 4
th passage in Vero E6 cells.
Insect cell-derived RVFV (IN-RVFV) was obtained by
propagating the passage 3 RVFV from Vero E6 cells above in a
mosquito cell line (C6/36, ATCC). C6/36 cells were infected at an
MOI of 0.1 and maintained at 28uC in a 1:1 mixture of EMEM
(Wisent) and ESF-921 (Expression Systems, Woodland, CA, USA)
supplemented with 2.5% FBS, 25 mM HEPES and 1 mM sodium
pyruvate. The IN-RVFV eventually used as inoculum for goats
was from the 2
nd passage in C6/36 cells.
The sequences for the M and S segments of MAM-RVFV and
IN-RVFV were compared for any differences that might result
from propagation in the different cell lines. The M segment was
selected for sequencing because it was recently shown that a
single nucleotide substitution in the glycoprotein (Gn) can have a
significant effect on the virulence of RVFV [24]. In addition, the
NSs protein encoded by the S segment is also of importance in
the virulence of RVFV [13,14,25]. For sequencing, viral RNA
was isolated as previously described [26] and RT-PCR performed
using published primers and protocol [27]. The RT-PCR
products were purified and then cloned using the cloneJet2.1/
blunt vector and the CloneJet PCR cloning kit (Fermentas,
Canada). Three positive clones per gene segment were identified
and sequenced and a consensus sequence obtained as previously
described [28].
Vero E6 cells were used to determine the titres of RVFV
derived from both cell lines. Briefly, serial 10 fold dilutions of virus
in 200 mL DMEM were transferred onto a 24-well plate
containing confluent Vero E6 cell monolayer. After 1 h, at
37uC, 5% CO2 and 95% relative humidity, an overlay of 1.75%
carboxymethylcellulose in DMEM containing 0.3% BSA (CMC
overlay) was added to all wells and plates incubated as above. After
4–5 days cells were fixed with 10% formalin, stained with 0.5%
crystal violet and plaques counted.
Author Summary
Rift Valley fever (RVF) is a mosquito-transmitted disease of
ruminants and man, which occurs in Africa, Saudi Arabia
and Yemen but could spread to other areas. There isn’t
much information on some aspects of the immune
response to this disease and how it affects cells of the
immune system in the natural animal hosts. To fill in some
of this knowledge gap, we studied RVF in goats
experimentally infected with the RVF virus. We also
compared RVF virus grown in an insect cell-line and that
grown in a mammalian cell-line for differences in the
course of infection. Virus was present in the blood of the
goats one day after infection. Some goats had fever
coinciding with the time when the virus level in the blood
was highest. Some cells in the blood dropped in number
possibly as a direct effect of virus. Infected goats secreted
cytokines (interferon gamma and interleukin-12), which
possibly contributed to protection against RVF. Virus from
an insect cell-line appeared to have more obvious effects
in infected goats suggesting that differences may exist in
infections of ruminants acquired from mosquito bites
compared to those due to contact with infectious material
from other animals.
Experimental Rift Valley Fever in Goats
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Healthy 4 month old Boer-cross goats were obtained from
breeders in Manitoba, Canada and allowed 10 days to acclimatize
to BSL3+ containment at NCFAD, during which they were
monitored daily for any signs of disease. After acclimatization, the
goats were divided into 2 groups (4 per group) and housed in
separate cubicles. One group was inoculated with 5 log10 PFU of
IN-RVFV and the 2
nd group with 5 log10 PFU of MAM-RVFV
per animal by the subcutaneous route. Daily monitoring was
continued and rectal temperatures recorded. Blood for serum
samples and for peripheral blood mononuclear cells (PBMCs)
isolation was collected prior to and daily for the first 7 days post
infection with RVFV. Additional sampling was done at 14, 21 and
30 DPI. Serum samples were stored at 270uC.
Peripheral blood mononuclear cells (PBMCs) isolation
and flow cytometry
Blood for PBMCs isolation was collected in EDTA-treated
vacutainers prior to and daily for the first 7 days post infection
(DPI) of goats with RVFV. PBMCs were purified from this blood
using Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) with minor modifications to manufacturer’s
protocol. Briefly, blood was mixed with an equal volume of sterile
phosphate buffered saline (PBS, pH 7.2, Sigma), layered over
Ficoll-Paque Plus and centrifuge at 800 g for 30 min with the
centrifuge brake off. The PBMC layer was collected and washed
twice with PBS.
The cells were then resuspended in FACS buffer (PBS
containing 0.1% BSA and 0.1% sodium azide) and stained for
flow cytometry using antibodies known to cross react with goat cell
surface markers [29]. Approximately 10
6 PBMCs/tube were each
stained with mouse anti bovine CD5:FITC (clone CC17), mouse
anti sheep CD8:RPE (clone 38.65), mouse anti bovine CD21:RPE
(cloneCC21) all from AbD Serotec (Oxford, UK) or mouse anti
CD172a (SWC3, clone DH59B) from VMRD (Pullman, WA,
USA) on ice for 30 min. Isotype control antibodies were included
to check for non-specific binding. Cells were washed twice with
FACS buffer and for CD172a (unlabelled primary antibody), rat
anti mouse IgG1:FITC (AbD Serotec) was added for another
30 min on ice.
For RVFV detection, PBMCs from infected goats were
permeabilized using BD cytofix:cytoperm reagent (BD Bioscienc-
es, San Diego, CA, USA) according to manufacturer’s protocol.
An optimal amount of rabbit polyclonal anti RVFV NSm1
antibody was then added to the cells and incubated on ice for
30 min. The rabbit polyclonal anti RVFV NSm1 antibody
(R1108) was produced by the EvoQuest Team, Invitrogen
(Carlsbad, California, USA) using a synthetic NSm1 polypeptide.
Antibody from a naı ¨ve rabbit was used as isotype control. Cells
were washed twice with BD perm/wash buffer, then stained with
Alexa Fluor 594 donkey anti rabbit IgG (Invitrogen, Oregun,
USA) for 30 min on ice, followed by 2 more washes with BD
perm/wash buffer.
After the final wash in all staining protocols, cells were fixed
overnight in 10% phosphate-buffered formalin before running on
the FC500 two laser flow cytometer (Beckman Coulter). At least
25,000 events were acquired per sample and data analysed with
the CXP analysis software (Beckman Coulter).
Generation and infection of goat monocyte-derived
dendritic cells
Peripheral blood mononuclear cells isolated from naı ¨ve goats as
described above were resuspended in RPMI supplemented with
10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin,
200 mM/mL glutamax, 10 mM HEPES and 0.5 mM 2-mercap-
toethanol (complete medium) and incubated in cell culture flasks at
37uC overnight for monocytes to attach. Non-adherent cells were
removed, adherent monocytes washed twice with sterile PBS and
then incubated at 37uC, 5% CO2 and 95% relative humidity in
complete medium containing 1 in 10 dilution of recombinant
bovine GM-CSF and 0.1 mg/mL recombinant bovine IL-4 (both
from Serotec). These conditions have been shown to differentiate
bovine monocytes into MoDCs [30]. As controls, adherent
monocytes were also cultured in complete medium only (MW).
Medium was supplemented after 3 days and MoDCs and MW
harvested after 7 days. Flow cytometry for CD14, CD172a and
CD11c surface markers was performed as described above.
For RVFV infection, approximately 5610
5 MoDCs were
exposed to either IN-RVFV or MAM-RVFV at 0.1 MOI in
RPMI without FBS for 1 h at 37uC, 5% CO2 and 95% relative
humidity. The cells were then washed, resuspended in complete
medium and incubated at 37uC for 24 h after which supernatants
were harvested. The amount of virus in culture supernatants was
measured by plaque assay on Vero E6 cells as described earlier.
Determination of adaptive cell-mediated immunity to
RVFV
Recall cell-mediated immunity (CMI) was determined by
measuring RVFV-specific IFN-c response [31] in PBMCs from
goats at DPI 21. Antigen-specific induction of IFN-c is one of the
accepted methods in immunology for detecting CMI. PBMCs
were isolated as described above and resuspended in complete
medium. PBMCs were adjusted to 10
7/mL, 100 mL added per
well of a 96-well plate and duplicate wells stimulated with IN-
RVFV or MAM-RVFV at 0.1 MOI to a final volume of 200 mL/
well. Complete medium was added to negative control wells while
ConA was used as positive control. Plates were incubated at 37uC,
5% CO2 and 95% relative humidity for 48 h, supernatants
harvested and stored at 270uC for subsequent IFN-c ELISA as
described below.
RNA extraction and qRT-PCR
RVFV RNA was extracted from serum using the TriPure
Isolation reagent (Roche) according to the manufacturer’s
protocol. The purified RNA was stored at 270uC. Primers
(Invitrogen) and probe (Applied Biosystems) designed to target
nucleotides 2912 to 2981 of the RVFV L gene segment [26,32]
were used for quantitative real-time reverse transcriptase poly-
merase chain reaction (qRT-PCR) as previously described [26].
Cytokine ELISA
Antibody pairs known to cross-react with goat IL-12 and IFN-c
were obtained from AbD Serotec and used as previously described
[29]. Based on the cross-reactivity of other bovine and ovine
antibodies with related targets in goats [29,33], there was a high
probability that other sheep and bovine cytokine ELISA
antibodies will also cross-react with goat. We therefore obtained
cytokine ELISA kits for sheep TNF-a, IL-6 and IL-1b from TSZ
ELISA (Framingham, MA, USA) and bovine IFN-a from USCN
Life Science Inc. (Wuhan, China) and used them with goat serum
according to the manufacturers’ instructions.
Interferon gamma antiviral assay
To test the in vitro antiviral effect of ruminant IFN-c against
RVFV, recombinant bovine IFN-c (RB- IFN-c, Thermo Scien-
tific) and Mardin-Darby bovine kidney (MDBK) cells were used.
Experimental Rift Valley Fever in Goats
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5 cells/well in 250 mL AMEM were added to
a 24-well plate and an equal volume of various concentrations of
RB- IFN-c added in quadruplicates. Medium only was added to
cells in the control wells. Plates were incubated at 37uC, 5% CO2
and 95% relative humidity for 24 h and checked for confluence.
Well contents were emptied and 100 PFU of RVFV in 200 mL
added to all wells except the cell controls. After 1 h at 37uC, CMC
overlay was added to all wells and plates incubated at 37uC, 5%
CO2 and 95% relative humidity. On day 3 after addition of virus,
cells were fixed with 10% formalin and stained with 0.5% crystal
violet. Plaques were counted in all wells and the percent plaque
inhibition calculated.
Antibody detection
Neutralising antibody response to RVFV was determined by
plaque reduction neutralization test (PRNT) modified from a
previously described protocol [34]. Serial 2-fold dilutions of serum
in DMEM were made starting from 1 in 20 to obtain triplicates of
100 mL/well for each serum sample. 100 mL of DMEM
containing 100 PFU of RVFV was added to each serum dilution,
mixed and incubated at 37uC, 5% CO2 and 95% relative
humidity for 1 h. 200 mL of the virus/serum mixture was then
transferred onto a 24-well plate containing confluent Vero E6 cell
monolayer and incubated for another 1 h. CMC overlay was then
added to all wells and plates incubated at 37uC, 5% CO2 and 95%
relative humidity. Assay of negative and positive control sera as
well as a back titration of the virus was performed at the same time
as the test sera. After 5 days the cells were fixed with 10%
formalin, stained with 0.5% crystal violet and plaques counted.
The reciprocal of the highest serum dilution that prevented at least
70% CPE was taken as the PRNT70 titre for that sample.
Statistical analysis
Data from multiple time points was analyzed by ANOVA with
the Dunnett multiple comparisons test using GraphPad InStat
version 3.06 (GraphPad Software, San Diego, CA). Differences
between groups for data collected at a single time point were
analysed using the Student t-test. A p # 0.05 was considered
statistically significant.
Results
Sequence identity of the Rift Valley fever virus
The M gene sequences of MAM-RVFV and IN-RVFV were
identical to each other (data not shown) as well as to a published
sequence for the M segment (GenBank accession number
DQ380200) of RVFV ZH501 strain [27]. Similarly, the gene
sequences for the S segment of MAM-RVFV, IN-RVFV and a
GenBank publication (accession number DQ380149) [27] were
identical to each other.
Viremia and clinical signs
All the goats infected with RVFV developed viremia starting at
DPI1. In IN-RVFV-infected goats, peak viremia was attained at DPI
1–2 and by DPI 4 all goats were aviremic (Figure 1A). On the other
hand, MAM-RVFV-infected goats had peak viremia at DPI 3 and at
DPI 4, 50% of the goats were still viremic (figure 1A). Indeed, on DPI
1 and 3 the difference in viremia between the 2 groups reached
statistical significance (p,0.02). Peak viremia in MAM-RVFV-
infected goats was higher than for IN-RVFV-infected goats but this
difference was not statistically significant. By DPI 5, no virus could be
detected in the blood of all the goats. The only clinical sign observed
was a slight increase in rectal temperature in IN-RVFV infected
goats. Following infection with IN-RVFV, rectal temperatures rose to
39.9–40.3uC,withmaximumtemperaturescorrespondingtopeaksof
viremia at DPI 1–2 (Figure 1B). In MAM-RVFV-infected goats, the
increase in rectal temperature was barely noticeable, with a
maximum of 39.9uCi n1g o a ta tD P I2 ,a n dn o te x c e e d i n g3 9 . 5 uC
in the rest of the goats (Figure 1B). However, there was no significant
difference in rectal temperatures between the 2 groups. All goats
survived through out the duration of the experiment.
Changes in frequencies of cell types in PBMCs of RVFV-
infected goats
Monocyte/DC, T lymphocytes, cytotoxic T cells and B cells were
identified with antibodies against CD172a, CD5, CD8 and CD21
surface markers respectively. Frequencies of these cells in naı ¨ve
goats ranged from 11.1–19.3% (CD172a+ monocytes/DC), 15.8–
35.4% (CD5+ T cells), 5.7–20.1% (CD8+ T cells) and 8.1–20.9%
(CD21+ B cells). Following infection there was a drop in CD172a+
monocytes/DC starting on DPI 2 in both IN-RVFV and MAM-
RVFV infected goats (Figure 2). However, this decline in CD172a+
monocytes/DC, expressed as a percentage of baseline frequencies,
was more pronounced and statistically significant (p,0.01 on DPI 2
and 4, p,0.05 on DPI 3) in IN-RVFV-infected goats compared to
MAM-RVFV-infected goats in which the drop never attained
statistical significance (figure 2). On the other hand, CD5+ T cells
and CD8+ T cells reduction was less than 20% in goats infected
with MAM-RVFV while goats infected with IN-RVFV suffered
approximately 40% drop (Figure 2). Conversely, in MAM-RVFV-
infected goats, CD21+ B cell frequencies increased by approxi-
mately 2 fold on DPI 1 and 2 (p,0.05 and p,0.01 respectively),
returning to within baseline values on DPI 3 but never dropping
below baseline frequencies (Figure 2). On the contrary, in IN-
RVFV-infected goats, the changes in CD21+ B cell frequencies
were not statistically significant, only increasing slightly on DPI 3
but declining to 30% below baseline frequencies on DPI 4 and 5
(Figure 2). However, by DPI 14, CD21+ B cell frequencies were
above baseline values in both groups.
Ex vivo infectivity of goat PBMC by RVFV
To investigate whether the decline in frequencies of identified
PBMC subsets was as a result of permissiveness to RVFV, PBMC
from infected goats were examined for the presence of virus by
intracellular staining for the non-structural protein (NSm1) and
flow cytometry. At DPI 1, 1.4 to 2% of PBMCs in MAM-RVFV
and IN-RVFV-infected goats were positive for RVFV which
increased to 3 to 4% on DPI 3 (Figure 3). More PBMCs stained for
NSm1 in IN-RVFV-infected than in MAM-RVFV-infected goats,
reaching statistical significance at DPI 1 (p # 0.05). However, this
difference was not statistically significant at DPI 3.
In vitro infectivity of goat MoDC by RVFV
Since goat MoDCs have not been previously described, we first
confirmed that the cells derived from goat monocytes with bovine
GM-CSF and IL-4 had the phenotype of related bovine MoDCs
[30,35]. These cells had the morphology of DC and were CD14
negative, CD11c and CD172a low as opposed to MW that were
CD14+, CD11c and CD172a high (supplementary figure 1).
When these cells were infected with RVFV at MOI 0.1,
approximately 1 log10 PFU/mL more virus (p,0.05) was
obtained from IN-RVFV-infected MoDCs compared to MAM-
RVFV at 24 h post infection (Figure 4).
Serum cytokine response to RVFV infection in goats
RVFV infection in goats was characterized by 2 cytokine
response patterns. Serum levels of IL-12 and IFN-c peaked early
Experimental Rift Valley Fever in Goats
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Serum IL-12 levels peaked at DPI 1 in both IN-RVFV-infected
and MAM-RVFV-infected goats (Figure 5). The increase in IL-12
response for IN-RVFV-infected goats reached statistical signifi-
cance on DPI 1 and 2 compared to baseline (p,0.01). On the
contrary, the increase in IL-12 response for MAM-RVFV-infected
goats did not reach statistical significance. The peak IL-12
response was significantly different between IN-RVFV-infected
and MAM-RVFV-infected goats (p=0.03). However, when all
infected goats were analysed together, the IL-12 response was
significant at DPI 1 (p,0.01) and DPI 2 (p,0.05). Maximum
levels of serum IFN-c was reached in IN-RVFV-infected goats at
DPI 2 but this was delayed until DPI 4 in MAM-RVFV-infected
goats (Figure 5). The IFN-c response reached statistical signifi-
cance on DPI 2 in IN-RVFV-infected goats (p,0.05) and DPI 4 in
MAM-RVFV-infected goats (p,0.05) compared to baseline.
There was no significant difference in peak IFN-c response
between the 2 groups. Serum TNF-a, IL-6 and IL-1b levels rose
slightly at DPI 1 followed by a significant increase (p,0.05) at DPI
6 (Figure 5). There were no significant differences between IN-
RVFV-infected and MAM-RVFV-infected goats with regards to
TNF-a, IL-6 and IL-1b response. Minute levels of IFN-a (#5 pg/
ml) were detected in serum from some naı ¨ve goats but these levels
did not increase early post infection (Figure 5).
In vitro antiviral effect of interferon gamma against RVFV
Due to the high serum IFN-c response in RVFV-infected goats,
direct antiviral effect of this cytokine on RVFV was tested in vitro
Figure 1. Viremia and rectal temperatures in Rift Valley fever virus (RVFV)-infected goats. A: Average viremia —&— in IN-RVFV and
—¤— MAM RVFV- infected goats (n=4 goats each). B: Average rectal temperature for —&— IN-RVFV and —¤— MAM RVFV- infected goats (n=4
goats each). Data points represent means + standard deviation. The average rectal temperature of the goats in the 7 days prior to challenge was
38.9uC60.5 standard deviation of mean. MAM-RVFV=RVFV produced in the mammalian cell line Vero E6, IN-RVFV=RVFV produced in the insect cell
line C6/36.
doi:10.1371/journal.pntd.0001623.g001
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from IN-RVFV-infected goats; Column B: PBMCs from MAM-RVFV-infected goats; Column C: Cell frequencies expressed as a percentage of pre-
infection value for —&— IN-RVFV and —¤—MAM RVFV- infected goats (n=4 goats each). Data points in column A and B represent individual
animals and the line represents the means. In column C data points represent means + standard deviation (error bars). MAM-RVFV=RVFV produced
in the mammalian cell line Vero E6, IN-RVFV=RVFV produced in the insect cell line C6/36.
doi:10.1371/journal.pntd.0001623.g002
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against RVFV, with only 21% plaque inhibition at 1000 ng/mL
(data not shown). In addition, this inhibition was dose dependent,
with none observed at 8 ng/mL concentration.
Adaptive cell-mediated immune response to RVFV
In vitro RVFV-induced IFN-c secretion by PBMCs from
convalescent goats was used to determine specific cell-mediated
immunity (CMI) [31]. PBMCs harvested from convalescent goats
at DPI 21 secreted high levels of IFN-c in response to RVFV re-
exposure (Figure 6). This IFN-c response was almost identical
between the IN-RVFV-infected and MAM-RVFV-infected goats
irrespective of which virus (IN-RVFV or MAM-RVFV) was used
for in vitro re-stimulation of PBMCs. In addition, the response to
the non-specific mitogen, ConA, was similar in both groups.
Unstimulated cells secreted significantly less IFN-c compared to
the cells exposed to either virus (p,0.02).
Antibody response in RVFV-infected goats
Antibody response, based on PRNT70, commenced on DPI 5
with low titres in most of the goats. Antibody titres rose to a
maximum at DPI 21–30 in all goats. However, PRNT70 titres for
IN-RVFV infected goats at DPI 7, 14 and 21 were significantly
lower (p,0.05) compared to MAM-RVFV infected goats
(Table 1). There was no significant difference in antibody response
between the 2 groups at DPI 30.
Discussion
Cattle, sheep and goats have long been recognized as the
natural hosts of RVFV. The clinical manifestation and pathology
of natural and experimental RVF in cattle and sheep have been
reported [8,31,36–38]. To the best of our knowledge, only one
report of experimental infection in goats is published, and it did
not address the innate immune response to the virus in goats [18].
Pathology following vaccination of goats with an attenuated strain
of RVFV has been studied. However reports from other models
reveal that this is not the same as infection with the virulent strain
[19]. In this report we attempted to address some aspects of the
innate and adaptive immune response to RVFV in goats. In
addition, we compared these parameters between insect cell-
derived and mammalian cell-derived RVFV. As in the previous
report [18], the incubation period for RVFV in goats was 24 h. A
similar incubation period is recorded for sheep, cattle, non-human
primates and humans [3]. Peak viremia at DPI 1–3 was similarly
reported in goats [18] and other susceptible species [3,11,31].
There were no mortalities and the only clinical sign we observed in
these RVFV-infected goats was a mild fever in a subset of animals.
Therefore, experimental infection of goats with RVFV produces a
fairly typical disease course similar to what has been observed in
other ruminants of a similar age group [3,18,31].
We observed a significant decline in CD172a+ cells (monocytes
and dendritic cells) in RVFV-infected goats. There was also a
pronounced decline in T cells (CD5+) and a transient decline in
cytotoxic lymphocytes (CD8+) in IN-RVFV infected goats. Only a
slight decline in the CD5 population was observed for MAM-
RVFV infected goats. It has been suggested that RVFV can
directly cause necrosis in infected cells as part of the disease
pathogenesis [25,39] and RVFV has been isolated from human
PBMCs in a natural outbreak [40]. RVFV has also been shown to
infect human monocytes/macrophages [25,41]. Furthermore,
RVFV was detected in Kupffer cells (resident liver macrophages)
[39]. The differential effect of IN-RVFV and MAM-RVFV on
PBMCs could be due to their differential ability to infect PBMC
subsets. Indeed, PBMCs from IN-RVFV-infected goats had
significantly higher percentage of RVFV NSm1 positive cells than
in their MAM-RVFV-infected counterparts at DPI 1 which might
be linked to the observation of a more profound decline in
CD172a+, CD5+ and CD8+ cells in IN-RVFV infected goats.
This is further supported by our in vitro data which shows that IN-
RVFV infects MoDCs more readily than does MAM-RVFV.
Furthermore, RVFV has previously been shown to infect MoDCs
[21]. In addition, in arboviruses, insect cell-derived alphaviruses
infect MoDCs more efficiently than mammalian cell-derived ones.
The presence of high mannose carbohydrates in the viral
glycoproteins is thought to enable the former to readily bind
receptors on target cells [20,22]. Contrary to the other cell subsets,
CD21+ B cell frequencies increased post infection and never
dropped below baseline in MAM-RVFV infected goats, while the
slight increase in CD21+ B cell frequencies in IN-RVFV infected
goats was followed by a decline below baseline frequencies. The
amplification of B cells probably prepared the immune system for
the more robust antibody production in MAM-RVFV infected
goats as opposed to in IN-RVFV infected ones.
Figure 3. Ex vivo infection of peripheral blood mononuclear
cells (PBMCs) in RVFV-infected goats. PBMCs isolated from goat
blood at indicated time points post RVFV infection were stained for
intracellular expression of RVFV non structural protein NSm1 and
infected cells identified by flow cytometry. Means of RVFV+ PBMCs from
IN-RVFV-infected goats are represented by the open histograms and
MAM-RVFV infected goats by the filled histograms. Error bars represent
standard deviation of means (n=3 goats each).
doi:10.1371/journal.pntd.0001623.g003
Figure 4. Virus yield from goat monocyte-derived dendritic
cells (MoDCs) inoculated with RVFV. MoDCs were infected with
insect cell-derived RVFV (IN-RVFV) or mammalian cell –derived RVFV
(MAM-RVFV) and after 24 h, the virus in supernatants was quantified by
plaque assay. Histograms represent means + standard deviation.
doi:10.1371/journal.pntd.0001623.g004
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ruminants has not been investigated. Here we report the detection
of IL-12, IFN-c, TNF-a, IL-6 and IL-1b in serum of RVFV-
infected goats. Also of significance, is the absence of detectable
IFN-a, one of the most potent antiviral cytokines. Experimental
models have demonstrated a role for IFN-a in RVFV clearance
[11] and the virus has developed mechanisms, via the NSs protein,
to inhibit IFN-a response in infected cells [12–14,25]. The
presence of other cytokines but not IFN-a in RVFV-infected goats
suggests that the virus may have specifically blocked its
production/induction. This would create a window for high
viremia to be attained which usually occurs within 24 h of
infection. On the other hand, IL-12 and IFN-c peaked at DPI 2–4
suggesting an otherwise functional innate immune response to
RVFV in goats. In previous reports in sheep, RVFV was cleared
from blood several days before the detection of neutralising
antibodies indicating that innate immunity was likely responsible
for this early protection [31]. IL-12 is known to activate bovine
Figure 5. Serum cytokine response in RVFV-infected goats. A: Interleukin (IL)-12, B: interferon gamma, C: Tumour necrosis factor alpha, D: IL-6
and E: IL-1b and F: interferon alpha. —&— IN-RVFV and —¤—MAM RVFV- infected goats (n=4 goats each). Data points represent means +
standard deviation. MAM-RVFV=RVFV produced in the mammalian cell line Vero E6, IN-RVFV=RVFV produced in the insect cell line C6/36.
doi:10.1371/journal.pntd.0001623.g005
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NK cells to better cytotoxicity [43]. The response pattern in the
current report suggests that IL-12 might have promoted the IFN-c
response, possibly from NK cells though other cells including
macrophages and DC also secrete IFN-c [44]. In previous studies
[10], monkeys were protected from RVF when human IFN-c was
administered 24 h prior to infection. In addition to promoting NK
cell cytotoxicity and downstream adaptive immune responses,
IFN-c is known to activate pathways that can directly inhibit virus
[43]. However, using recombinant bovine IFN-c, we did not
detect any significant direct antiviral effect on RVFV replication in
MDBK cells. Indeed, there was no antiviral effect at titres
equivalent to the maximum serum IFN-c response in RVFV-
infected goats. Furthermore, it has been demonstrated that human
IFN-c has minimal in vitro antiviral effect against RVFV [45]. It is
therefore, possible that IFN-c and IL-12 may have played a role in
the rapid clearance of viremia in RVFV-infected goats by
activating NK cells, even though a direct antiviral effect of these
cytokines can not be ruled out. This will be investigated in
subsequent experiments. The other pro-inflammatory cytokines
may have also played a role in RVFV clearance despite reaching
peak levels on DPI 6–7. Recent data from humans suggests that a
strong pro-inflammatory response is linked to survival of RVF
[25].
The detection of neutralising antibodies starting at DPI 5
reported here has been similarly observed in natural and
experimental infections in other animal models and humans
[2,15–17]. Neutralising antibodies are believed to be crucial for
the early protection against RVFV [2]. Based on our observations
in goats, the initial protection could be primarily due to innate
immunity (mediated by cytokines and possibly NK cells).
Nevertheless, neutralising antibodies are responsible for long term
protection from subsequent challenge [2]. Adaptive cell mediated
immunity may also be involved in long term protection from
Figure 6. Adaptive cell mediated immunity in RVFV-infected goats. Means of PBMC IFN-c response from IN-RVFV-infected goats are
represented by the open histograms and MAM-RVFV infected goats by the filled histograms. Error bars represent standard deviation of means (n=4
goats each). MAM-RVFV=RVFV produced in the mammalian cell line Vero E6, IN-RVFV=RVFV produced in the insect cell line C6/36.
doi:10.1371/journal.pntd.0001623.g006
Table 1. Antibody response in RVFV-infected goats.
PRNT70 titre
Group Goat # DPI 0 DPI 4 DPI 5 DPI 6 DPI 7 DPI 14 DPI 21 DPI 30
MAM-RVFV 4 ,20 ,20 20 40 40 320 640 640
27 ,20 ,20 20 40 80 320 640 640
28 ,20 ,20 20 20 80 320 1280 5120
44 ,20 ,20 20 40 40 320 1280 640
IN-RVFV 29 ,20 ,20 20 20 20 80 320 320
38 ,20 ,20 20 20 40 40 320 640
39 ,20 ,20 20 20 20 40 320 640
48 ,20 ,20 40 40 40 40 320 640
Antibody response to RVFV was measured by plaque reduction neutralisation test (PRNT). The reciprocal of the serum dilution giving at least 70% plaque inhibition
relative to the virus control was taken as the PRNT70 titre for that sample. MAM-RVFV=mammalian cell-derived RVFV, IN-RVFV=insect cell-derived RVFV.
doi:10.1371/journal.pntd.0001623.t001
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restimulation of cells from convalescent goats (this report) and
sheep [31]. Experimental trials in mice have also suggested that
cell mediated immunity is important for post-vaccinal protection
against RVFV [46].
In conclusion, experimental RVF in goats closely resembles
natural and experimental infection in other ruminant hosts.
Apparently, the virus infects DCs and monocytes and inhibits IFN-
a response thereby allowing rapid replication. However other
arms of innate and possibly adaptive immunity combine to protect
animals from RVFV shortly after infection. The source of virus
appears to influence events during infection, with IN-RVFV
attaining peak viremia more rapidly, infecting more PBMCs,
inducing slight fever and higher levels of early cytokines but lower
levels of neutralising antibodies at onset of seroconversion. These
findings seem to suggest that infections acquired from mosquito
bites could differ somewhat from those due to contact with
infectious material. However, this is far from conclusive consid-
ering the small sample size of 4 goats per group and the fact that in
a natural setting things are much more complex, with other factors
such as dose of infection, age and immune status likely to influence
the course of disease. In addition, considering that these are
outbred animals, genetic factors could also have contributed to the
observed differences. Nevertheless, all 8 goats responded to RVFV
by secreting cytokines irrespective of the source of virus. More
work is required in goats and other ruminants to check if these
results can be similarly observed in these species.
Supporting Information
Figure S1 Phenotype of goat monocyte-derived dendrit-
ic cells. MoDCs were differentiated from adherent blood
monocytes using recombinant bovine GM-CSF and IL-4. For
controls, adherent monocytes were cultured in culture medium
only (MW). Pictures were taken on days 0, 3 and 6. On day 7,
MoDCs and MW were harvested and analyzed by flow cytometry.
1A. shows progression from monocytes to MoDCs with charac-
teristic dendrites. 1B. shows MoDCs (broken line) as CD14
negative, CD172a and CD11c low as opposed to MW (solid line)
that were CD14+, CD172a and CD11c high. Filled histograms
represent cells stained with isotype control antibody.
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